story of the week
Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
J. Clin. Oncol 2022 Jun 15;[EPub Ahead of Print], TM Kadia, PK Reville, X Wang, CR Rausch, G Borthakur, N Pemmaraju, NG Daver, CD DiNardo, K Sasaki, GC Issa, M Ohanian, G Montalban-Bravo, NJ Short, N Jain, A Ferrajoli, KN Bhalla, E Jabbour, K Takahashi, R Malla, K Quagliato, R Kanagal-Shamanna, UR Popat, M Andreeff, G Garcia-Manero, MY Konopleva, F Ravandi, HM KantarjianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.